back to US directory
us clinical guidance

Ritlecitinib for severe alopecia areata

June 2026 FDA-labeled use of ritlecitinib for adults and adolescents aged 12 years or older, including baseline testing and JAK-class safety.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults and adolescents aged 12 years or older with severe alopecia areata being considered for ritlecitinib. Use with another JAK inhibitor, biologic immunomodulator, cyclosporine or another potent immunosuppressant is not recommended.
sources for this section:FDA Litfulo label 2026

The Bottom Line

  • Confirm severe alopecia areata and document scalp, eyebrow, eyelash, nail and quality-of-life impact; exclude scarring, fungal and other causes before systemic treatment.
  • The June 2026 FDA label indicates ritlecitinib for severe alopecia areata in adults and adolescents 12 years and older and specifies one labeled daily capsule regimen; do not extrapolate the indication to younger children.
  • Before initiation, evaluate tuberculosis and viral hepatitis, obtain absolute lymphocyte and platelet counts, update immunizations and assess liver enzymes and the broader infection, malignancy, cardiovascular and thrombosis context.
  • Do not begin when absolute lymphocyte or platelet values are below the label’s initiation thresholds, during active tuberculosis or serious infection, or in severe hepatic impairment; follow exact interruption and discontinuation rules.
  • The 2026 label adds hypoglycemia risk in patients with diabetes, requiring symptom counseling and consideration of increased glucose monitoring after treatment starts.
sources for this section:FDA Litfulo label 2026

Practical clinical workflow

1
Verify age, severe disease extent, tempo, prior treatment and patient goals, and review smoking, cardiovascular, thrombotic, infection, malignancy, hepatic, reproductive and vaccination history.
2
Perform tuberculosis and hepatitis screening, absolute lymphocyte and platelet counts and baseline liver assessment; address latent tuberculosis and bring immunizations, including zoster vaccination where appropriate, up to date before treatment.
3
Explain the boxed warnings, serious infection precautions, interactions, avoidance of live vaccines, pregnancy and lactation considerations, glucose awareness in diabetes and when to seek urgent care.
4
Measure response with the same scalp and non-scalp baseline tools, repeat lymphocyte and platelet counts at four weeks and thereafter according to the current label and routine management, and investigate liver-enzyme elevation or muscle symptoms as indicated.
5
Interrupt or discontinue at the exact FDA thresholds for hematologic abnormality and for serious infection, hypersensitivity, thrombosis, myocardial infarction or stroke; reassess benefit when adequate regrowth is not achieved.
sources for this section:FDA Litfulo label 2026

Safety boundaries and escalation

  • Ritlecitinib carries a boxed warning for serious infection, mortality, malignancy, major adverse cardiovascular events and thrombosis; risk discussion must be individualized, especially for current or past smokers and patients with cardiovascular risk.
  • Avoid live vaccines during or shortly before therapy and monitor for tuberculosis, herpes zoster and other serious or opportunistic infections during and after treatment.
  • Suspected thrombosis or embolism requires interruption and prompt evaluation; the label directs discontinuation after myocardial infarction or stroke.
  • Monitor absolute lymphocytes, platelets, liver enzymes and clinically relevant creatine phosphokinase findings under the current label, and increase glucose vigilance in patients with diabetes because severe hypoglycemia has been reported after JAK-inhibitor initiation.
sources for this section:FDA Litfulo label 2026

Localization

Payer authorization may ask for a severity measure but does not replace the labeled indication, contraindications or monitoring. The June 2026 label was directly checked on 2026-08-20 and must be rechecked before prescribing and at each scheduled review.
sources for this section:FDA Litfulo label 2026

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Food and Drug AdministrationLITFULO (ritlecitinib) capsules, for oral use — Prescribing InformationNDA 215830/S-001 · Reference ID 5826025 · Revised June 2026 · accessed 2026-08-20
    view source
  2. American Academy of DermatologyAlopecia areata: Diagnosis and treatmentaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.